Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB has commenced a clinical phase Ib/II study of arfolitixorin, a potential treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to assess the benefit/risk profile of escalating doses in a new dosing regimen, with the goal of optimizing the drug’s efficacy. This milestone marks significant progress in Isofol’s plan to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for various solid tumors, particularly in colorectal cancer, which is the third most common cancer globally. Isofol Medical AB is listed on Nasdaq Stockholm.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.